Capricor Therapeutics Reports Widened Q1 Loss, Details Lawsuit Against Distributor NS Pharma
summarizeSummary
Capricor Therapeutics reported a widened Q1 loss and increased cash burn, while detailing a critical lawsuit against its U.S. distributor that threatens the commercialization of its lead drug, Deramiocel.
check_boxKey Events
-
Widened Q1 Net Loss
The company reported a net loss of $33.9 million for Q1 2026, compared to $24.4 million for Q1 2025.
-
Increased Cash Burn
Net cash used in operating activities significantly increased to $29.3 million in Q1 2026 from $6.4 million in Q1 2025.
-
Lawsuit Against Distributor
Capricor filed a lawsuit against NS Pharma, its exclusive U.S. distributor for Deramiocel, alleging a fundamental pricing flaw and material breach of their distribution agreement. The company seeks rescission of the agreement and the right to distribute Deramiocel directly.
-
Deramiocel FDA Review Continues
The Biologics License Application (BLA) for Deramiocel remains under FDA Priority Review, with a PDUFA target action date of August 22, 2026.
auto_awesomeAnalysis
Capricor Therapeutics reported a significantly widened net loss and increased cash burn for Q1 2026. The company also provided extensive details on its recently filed lawsuit against its U.S. distributor, NS Pharma, alleging a fundamental pricing flaw and material breach of their Deramiocel distribution agreement. This legal dispute introduces substantial uncertainty and risk to the commercialization strategy for Deramiocel, the company's lead product, especially with its FDA PDUFA date approaching in August 2026.
At the time of this filing, CAPR was trading at $30.33 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $4.30 to $40.37. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.